Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2012

01.09.2012 | short review

Treating T-cell lymphoma: is there a light at the end of the tunnel?

verfasst von: Georg Hopfinger, Olaf Merkel, Thomas Melchardt, Richard Greil

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Treating peripheral T-cell lymphomas (PTCL) remains a clinical challenge harbouring an often aggressive course and furthermore, no standard therapy is established. In more detail, PTCL comprises a heterogeneous group of haematological tumours constituting less than 15 % of all non-Hodgkin’s lymphomas (NHLs) in adults in the western hemisphere. The following short review will provide an up-date based on data presented at ASH meeting 2011 in PTCL providing improved understanding of patho-mechanism and further development of more specific therapy options.
Literatur
1.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, et al. (eds.) WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC. 2008;2(2):439. Swerdlow SH, Campo E, Harris NL, et al. (eds.) WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC. 2008;2(2):439.
2.
Zurück zum Zitat Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011 Jun 23;117(25):6756–67.PubMedCrossRef Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011 Jun 23;117(25):6756–67.PubMedCrossRef
3.
Zurück zum Zitat Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008 Sept 1;26(25):4124–30.PubMedCrossRef Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008 Sept 1;26(25):4124–30.PubMedCrossRef
4.
Zurück zum Zitat Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood. 2008 Jun 15;111(12):5496–504.PubMedCrossRef Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood. 2008 Jun 15;111(12):5496–504.PubMedCrossRef
5.
Zurück zum Zitat Tang T, Allen G, Koo GC, Tay K, Tan D, Quek R, et al. Gene expression profiling identifies the JAK/STAT and NF kappa B pathways to be important in peripheral T-cell lymphomas and natural-killer T-cell lymphomas. Blood. 2011 Nov 18;118(21):1142 (#2658). Tang T, Allen G, Koo GC, Tay K, Tan D, Quek R, et al. Gene expression profiling identifies the JAK/STAT and NF kappa B pathways to be important in peripheral T-cell lymphomas and natural-killer T-cell lymphomas. Blood. 2011 Nov 18;118(21):1142 (#2658).
6.
Zurück zum Zitat Martin-Sanchez E, Rodriguez-Pinilla SM, Lombardia L, Dominguez-Gonzalez B, Sanchez-Beato M, Romero D, et al. PI3 K inhibition as a potential therapeutic strategy in peripheral T-cell lymphomas. Blood. 2011 Nov 18;118(21):1490–1 (#3494). Martin-Sanchez E, Rodriguez-Pinilla SM, Lombardia L, Dominguez-Gonzalez B, Sanchez-Beato M, Romero D, et al. PI3 K inhibition as a potential therapeutic strategy in peripheral T-cell lymphomas. Blood. 2011 Nov 18;118(21):1490–1 (#3494).
7.
Zurück zum Zitat Marchi E, Kalac M, Bongero DC, McIntosh CM, Fogli LK, Scotto L, et al. Combination of epigenetic agents synergistically reverse the malignant phenotype in models of T-cell lymphoma. Blood. 2011 Nov 18;118(21):1173 (#2727). Marchi E, Kalac M, Bongero DC, McIntosh CM, Fogli LK, Scotto L, et al. Combination of epigenetic agents synergistically reverse the malignant phenotype in models of T-cell lymphoma. Blood. 2011 Nov 18;118(21):1173 (#2727).
8.
Zurück zum Zitat Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK+ and ALK−) anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A. 2010 Sept 14;107(37):16228–33.PubMedCrossRef Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK+ and ALK−) anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A. 2010 Sept 14;107(37):16228–33.PubMedCrossRef
9.
Zurück zum Zitat Piccaluga PP, Laginestra MA, Rossi M, De Leo A, Gibellini D, Gazzola A, et al. Identification of differentially expressed miRNAs in peripheral t-cell lymphomas. Blood. 2011 Nov 18;118(21):350–1 (#773). Piccaluga PP, Laginestra MA, Rossi M, De Leo A, Gibellini D, Gazzola A, et al. Identification of differentially expressed miRNAs in peripheral t-cell lymphomas. Blood. 2011 Nov 18;118(21):350–1 (#773).
10.
Zurück zum Zitat Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group. Blood. 2010 Nov 4;116(18):3418–25.PubMedCrossRef Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group. Blood. 2010 Nov 4;116(18):3418–25.PubMedCrossRef
11.
Zurück zum Zitat Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1 H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007 Oct 1;110(7):2316–23.PubMedCrossRef Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1 H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007 Oct 1;110(7):2316–23.PubMedCrossRef
12.
Zurück zum Zitat Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60(1):129–34.CrossRef Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60(1):129–34.CrossRef
13.
Zurück zum Zitat Dunleavy K, Shovlin M, Pittaluga S, Grant C, Steinberg SM, Jaffe ES, et al. DA-EPOCH chemotherapy is Highly effective in ALK-positive and ALK-negative ALCL: results of a prospective study of PTCL subtypes in adults. Blood. 2011 Nov 18;118(21):704 (#1618). Dunleavy K, Shovlin M, Pittaluga S, Grant C, Steinberg SM, Jaffe ES, et al. DA-EPOCH chemotherapy is Highly effective in ALK-positive and ALK-negative ALCL: results of a prospective study of PTCL subtypes in adults. Blood. 2011 Nov 18;118(21):704 (#1618).
14.
Zurück zum Zitat Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009 Jan 1;27(1):106–13.PubMedCrossRef Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009 Jan 1;27(1):106–13.PubMedCrossRef
15.
Zurück zum Zitat Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo study group. Eur J Haematol. 2007 Jul;79(1):32–8.PubMedCrossRef Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo study group. Eur J Haematol. 2007 Jul;79(1):32–8.PubMedCrossRef
16.
Zurück zum Zitat d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. High-dose chemotherapy and autologuos stem cell transplantation in previously untreated peripheral T-cell lymphoma—final analysis of a large prospective multicenter study (NLG-T-01). Blood. 2011 Nov 18;118(21):155–6 (#331). d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. High-dose chemotherapy and autologuos stem cell transplantation in previously untreated peripheral T-cell lymphoma—final analysis of a large prospective multicenter study (NLG-T-01). Blood. 2011 Nov 18;118(21):155–6 (#331).
17.
Zurück zum Zitat d’Amore F, da Silva MG, Leppa S, Relander T, Pezzutto A, Lauritzsen GF, et al. First interim safety analysis of a phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood. 2011 Nov 18;118(21):1755 (#4110). d’Amore F, da Silva MG, Leppa S, Relander T, Pezzutto A, Lauritzsen GF, et al. First interim safety analysis of a phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood. 2011 Nov 18;118(21):1755 (#4110).
18.
Zurück zum Zitat O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182–9.PubMedCrossRef O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182–9.PubMedCrossRef
19.
Zurück zum Zitat Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20;30(6):631–6.PubMedCrossRef Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20;30(6):631–6.PubMedCrossRef
20.
Zurück zum Zitat Dupuis J, Casasnovas RO, Morschhauser F, Ghesquieres H, Thieblemont C, Ribrag V, et al. Early results of a phase Ib/II dose-escalation trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphomas (PTCL). Blood. 2011 Nov 18;118(21):1148 (#2673). Dupuis J, Casasnovas RO, Morschhauser F, Ghesquieres H, Thieblemont C, Ribrag V, et al. Early results of a phase Ib/II dose-escalation trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphomas (PTCL). Blood. 2011 Nov 18;118(21):1148 (#2673).
21.
Zurück zum Zitat Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 Nov 4;363(19):1812–21.PubMedCrossRef Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 Nov 4;363(19):1812–21.PubMedCrossRef
22.
Zurück zum Zitat Advani RH, Shustov AR, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: a phase 2 study update. Blood. 2011 Nov 18;118(21):204 (#443). Advani RH, Shustov AR, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: a phase 2 study update. Blood. 2011 Nov 18;118(21):204 (#443).
23.
Zurück zum Zitat Friedberg J, Mahadevan D, Jung J, Persky DO, Lossos IS, Danaee H, et al. Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL). Blood. 2011 Nov 18;118(21):46 (+#95). Friedberg J, Mahadevan D, Jung J, Persky DO, Lossos IS, Danaee H, et al. Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL). Blood. 2011 Nov 18;118(21):46 (+#95).
Metadaten
Titel
Treating T-cell lymphoma: is there a light at the end of the tunnel?
verfasst von
Georg Hopfinger
Olaf Merkel
Thomas Melchardt
Richard Greil
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0013-4

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012 Zur Ausgabe